ArticleDiabetology & metabolic syndrome2025
Semaglutide and adenosine alleviate obesity-induced kidney injury, with observed modulation of the Txnip/NLRP3 pathway.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in proteomics research related to semaglutide: evidence from humans and animals.Journal of endocrinological investigation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis study was designed to evaluate the effects of Semaglutide and adenosine on kidney protein expression in obese mice induced by a high-fat diet (HFD), to identify signaling pathways involved in the obesity-related glomerulonephropathy (ORG) regulation using a proteomics approach. MATERIALS AND
methodsA total of 48 mice were divided into normal-fat diet (NFD), high-fat diet (HFD), HFD + semaglutide intervention (HS), and HFD + adenosine intervention (HA) groups. Mouse serum, urine, and kidney tissue samples were collected to identify markers for blood glucose lipid metabolism, inflammation, oxidative stress (OS), kidney damage protein, urinary protein/creatinine, and other relevant factors. The kidney pathological changes of mice were observed under light and electron microscope. The differences in total proteins in the kidneys of mice were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The proteins with significant differences were selected for bioinformatics and Western Blot (WB) analyses.
resultsSemaglutide and adenosine can reduce the weight of obese mice, improve the level of glucose and lipid metabolism, inflammation, and OS in obese mice, and have a positive effect on glomerular and tubular lesions in mice. The TXNIP/NLRP3 signaling pathway, which is involved in the pathogenesis of murine ORG, was screened using a proteomics approach. Western Blot showed that the expressions of Txn, Txnip, and NLRP3 in HFD mice were significantly higher than those of NFD mice, while the expression levels of Txn, Txnip, and NLRP3 in HS and HA mice were substantially lower than those of HFD mice.
conclusionSemaglutide and adenosine can ameliorate obesity-induced renal injury, potentially through modulation of the Txnip/NLRP3 pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.